The current role of telomerase in the diagnosis of bladder cancer

Indian Journal of Urology

Volumn 25, Issue 1, 2009, Pages 40-46

  Silvestrini, Rosella ^a   Bravaccini, Sara ^a   Casadio, Valentina ^a   Amadori, Dino ^a   Calistri, Daniele ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Bladder cancer; Early diagnosis; Telomerase; Telomerase repeat amplification protocol

Indexed keywords

MONOCLONAL ANTIBODY; NUCLEAR MATRIX PROTEIN 22; POLYCLONAL ANTIBODY; TELOMERASE; TUMOR ANTIGEN; TUMOR MARKER;

ASSAY; BLADDER CANCER; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL PROTOCOL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; EARLY DIAGNOSIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNORADIOMETRIC ASSAY; NON INVASIVE PROCEDURE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; URINE;

EID: 60849087968     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.45535     Document Type: Review

References (57)

1. American Cancer Society. Cancer Facts and Figures 2004. Atlanta, Ga: American Cancer Society; 2004.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Rehn L. Blasengeschwülste bei Fuchsin-arbeitern. Arch Clin Chir 1895;50:588-600.
4. American College of Surgeons. Commission on Cancer National Cancer Database. Available from: http://www.facs.org/cancer/ncdb/index.html. [Last accessed 2, December 2008].
5. Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Bram LL, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995;45:387-96;discussion 396-7.
6. Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006;107:2173-9.
7. Müller M. Telomerase: Its clinical relevance in the diagnosis of bladder cancer. Oncogene 2002;21:650-5.
8. Kriegmair M, Baumgartner R, Knüchel R, Stepp H, Hofstädter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence J Urol 1996;155:105-9.
9. Abel PD. Prognostic indices in transitional cell carcinoma of the bladder. Br J Urol 1988;62:103-9.
10. Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945;101:519-20.
11. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950-4.
12. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164:1768-75.
13. Placer J, Espinet B, Salido M, Solé F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 2002;42:547-52.
14. Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria MV, Crawford ED. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol 2004;22:16-9.
15. May M, Hakenberg OW, Gunia S, Pohling P, Helke C, Lübbe L, et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology 2007;70:449-53.
16. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, et al Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101-5.
17. Riesz P, Lotz G, Páska C, Szendrôi A, Majoros A, Németh Z, et al. Detection of Bladder Cancer from the urine using fluorescence in situ hybridization technique. Pathol Oncol Res 2007;13:187-94.
18. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis Urovysion assays for the detection of urothelial carcinoma in urine. J Urol 2002;167:2001-6.
19. Laudadio J, Keane TE, Reeves HM, Savage SJ, Hoda RS, Lage JM, et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: Implications for clinical practice. BJU Int 2005;96:1280-5.
20. Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006;176:44-7.
21. Adb El Gawad IA, Moussa HS, Nasr MI, El Gemae EH, Masooud AM, Ibrahim IK, et al. Comparative study of NMP-22, telomerase and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst 2005;17:193-202.
22. Babjuk M, Kostírová M, Mudra K, Pecher S, Smolová H, Pecen L, et al. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur Urol 2002;41:34-9.
23. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002;89:369-73.
24. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal. A Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999;162:53-7.
25. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998;52:398-402.
26. Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa. A Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol 2002;168:465-9.
27. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;16:810-6.
28. Atsü N, Ekici S, Oge O, Ergen A, Hasçelik G, Ozen H. False-positive results of the NMP22 test due to hematuria. J Urol 2002;67:555-8.
29. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995;269:1236-41.
30. Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, et al. A mammalian telomerase-associated protein. Science 1997;275:973-7.
31. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-9.
32. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
33. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996;18:173-9.
34. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
35. Fedriga R, Gunelli R, Nanni O, Bacci F, Amadori D, Calistri D. Telomerase activity detected by quantitative assay in bladder carcinoma and exfoliated cells in urine. Neoplasia 2001;3:446-50.
36. Sanchini MA, Bravaccini S, Medri L, Gunelli R, Nanni O, Monti F, et al. Urine telomerase: An important marker in the diagnosis of bladder cancer. Neoplasia 2004;6:234-9.
37. Sanchini MA, Gunelli R, Nanni O, Bravaccini S, Fabbri C, Sermasi A, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 2005;294:2052-6.
38. Weikert S, Krause H, Wolff I, Christoph F, Schrader M, Emrich T, et al. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int J Cancer 2005;117:274-80.
39. Soldateschi D, Bravaccini S, Berti B, Brogi A, Benicchi T, Soldatini C, et al. Development and characterization of a monoclonal antibody directed against human telomerase reverse transcriptase (hTERT). J Biotechnol 2005;118:370-8.
40. Volpi A, Bravaccini S, Medri L, Cerasoli S, Gaudio M, Amadori D. Usefulness of immunological detection of the human telomerase reverse transcriptase. Cell Oncol 2005;27:347-53.
41. Hiyama E, Hiyama K, Yokoyama T, Shay JW. Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia 2001;3:17-26.
42. Yokota K, Kanda K, Inoue Y, Kanayama H, Kagawa S. Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma. Br J Urol 1998;82:727-32.
43. Wright WE, Shay JW, Piatyszek MA. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 1995;23:3794-5.
44. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 1997;25:2595-7.
45. Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998;82:708-14.
46. Gelmini S, Crisci A, Salvadori B, Pazzagli M, Selli C, Orlando C. Comparison of telomerase activity in bladder carcinoma and exfoliated cells collected in urine and bladder washings, using a quantitative assay. Clin Cancer Res 2000;6:2771-6.
47. Bravaccini S, Sanchini MA, Granato AM, Gunelli R, Nanni O, Amadori D, et al. Urine telomerase activity for the detection of bladder cancer in females. J Urol 2007;178:57-61.
48. Lotan Y, Svatek RS, Sagalowsky Al. Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer 2006;107:982-90.
49. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002;66:407-25.
50. Horikawa I, Barrett JC. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 2003;24:1167-76.
51. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-95.
52. de Kok JB, Ruers TJ, van Muijen GN, van Bokhoven A, Willems HL, Swinkels DW. Real-time quantification of human telomerase reverse transcriptase mRNA in tumors and healthy tissues. Clin Chem 2000;46:313-8.
53. Takihana Y, Tsuchida T, Fukasawa M, Araki I, Tanabe N, Takeda M. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer. Int J Urol 2006;13:401-8.
54. Bowles L, Bialkowska-Hobrzanska H, Bukala B, Nott L, Razvi H. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer. Can J Urol 2004;11:2438-44.
55. Eissa S, Swellam M, Ali-Labib R, Mansour A, El-Malt O, Tash FM. Detection of telomerase in urine by 3 methods: Evaluation of diagnostic accuracy for bladder cancer. J Urol 2007;178:1068-72.
56. Khalbuss W, Goodison S. Immunohistochemical detection of hTERT in urothelial lesions: A potential adjunct to urine cytology. Cytojournal 2006;3:18.
57. Liu K, Hodes RJ, Weng Np. Cutting edge: Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. Immunol 2001;166:4826-30.